Amy B. Heimberger

Professor

Northwestern University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (26)

Meningiomas are the most common primary brain tumors and, despite their benign reputation, often behave aggressively. Meningiomas are morphologically heterogeneous, yet the full significance of their histologic diversity is unclear. This is in large part because many features are not readily quantifiable by traditional observer-based light microscopy. Molecular testing improves prognostic stratification, but is not universally accessible. We therefore sought to determine whether an artificial intelligence (AI)-trained program could predict specific genomic and epigenomic patterns in meningiomas, and whether it could extract more prognostic information out of standard hematoxylin and eosin (H&E) histopathology than the current WHO classification. To do this, we developed Morphologic Set Enrichment (MSE), an interpretable computational pathology framework that quantifies statistical enrichment of morphologic patterns, cells, and tissue architecture from H&E whole-slide images. The MSE meningioma histology program was able to accurately predict DNA methylation subtypes and concurrent chromosome 1p/22q losses, in the process identifying specific morphologic patterns associated with key genomic and epigenomic alterations. It also added prognostic value independent of standard clinical and pathological variables. These results demonstrate that AI-based quantitative morphologic profiling can capture clinically and biologically relevant information that redefines risk stratification for meningiomas, incorporating histological information not included in existing grading schemes.

Year:

2026

The cyclic GMP-AMP synthase-Stimulator of Interferon Genes (cGAS–STING) pathway is an important DNA-sensing mechanism that increases T cell trafficking and activation in tumors and reverses the immunosuppressive phenotype of myeloid cells. Therefore, direct STING targeting using synthetic cyclic dinucleotides (CDNs) is an attractive strategy for treating lymphocyte-depleted and myeloid cell–enriched tumors, such as glioblastoma (GBM). However, inadequate bioavailability and poor cellular accumulation limit the clinical development of CDNs, particularly for noninvasive administration strategies. Spherical nucleic acids (SNAs) have emerged as promising modular constructs for creating therapeutic lead compounds for many diseases, including different forms of cancer. Here, we report the development of cGAS-activating SNAs that consist of gold nanoparticle cores functionalized with a shell of densely packed interferon-stimulatory DNA oligonucleotides (ISD 45 -SNAs). These nanostructures bind to cGAS, the sensor of cytosolic dsDNA upstream of STING, promoting the catalytic production of endogenous CDNs and downstream STING activation more potently than clinically tested CDNs. When administered intranasally or intratumorally to poorly immunogenic syngeneic GBM mouse models, ISD 45 -SNAs inhibit tumor growth more effectively than CDNs and promote long-term animal subject survival through specific cGAS–STING pathway activation. ISD 45 -SNAs induce a proinflammatory immune microenvironment enriched with effector T cells and proinflammatory macrophages. When coadministered with immune checkpoint inhibitors (ICI), they abolish GBM tumor development and induce long-term antiglioma immunity. These studies establish ISD 45 -SNAs as an immune-stimulatory modality for triggering innate and adaptive immune responses and increasing ICI efficacy for GBM treatment.

Year:

2025

This phase I trial evaluated the IDO1 enzyme inhibitor, BMS-986205, with radiation (RT) and nivolumab treatment in newly diagnosed patients with GBM IDHwt. Cohort A received RT + nivolumab with escalating BMS-986205 doses in MGMT unmethylated GBM patients. Cohort B received the highest dose of BMS-986205 with nivolumab and standard RT/temozolomide (TMZ) 🡢TMZ in MGMT methylated GBM patients. The treatments were found to be safe and tolerable. The median overall survival was 11.5 (95% CI: 3.71, 33.8) and 26.9 months (95% CI: 8.94-NR) while the 2-year survival rates were 33% (95% CI: 10.3%, 58.8%) and 60% (95% CI: 12.6%, 88.2%) for MGMT unmethylated and methylated GBM, respectively. Longer patient survival was associated with higher CD8 + T cell levels, higher microbial aryl-lactate levels, higher abundance of Massilioclostridium coli , Dysosmobacter welbionis , and Phocaeicola plebeius in the stool, a younger age, and a lack of gross total resection. (ClinicalTrials.gov: NCT04047706).

Year:

2025

Background Therapeutic resistance in glioblastoma (GBM) is multifactorial and results from genetic heterogeneity, the immunoprivileged localization, and the potently tolerogenic microenvironment. Signal transducer and activator of transcription 3 (STAT3) plays a key role in both glioma cell survival and immune evasion, reinforcing GBM resistance. Methods Here, we describe a new cell-selective and double-stranded STAT3 antisense oligonucleotide (CpG-STAT3dsASO) for targeting human/mouse glioma cells and GAMs but not T cells. The oligonucleotide safety and efficacy against orthotopic GBM was assessed in immunocompetent or immunodeficient mice. Results CpG-STAT3dsASO injected intracranially/intratumorally was well-tolerated and reduced progression of human U251 GBM xenotransplants and mouse GL261 or neural cell-derived QPP8 gliomas. Unlike the single-stranded oligonucleotide, local CpG-STAT3dsASO administration did not trigger type-I IFN-dependent neurotoxicities in immunocompetent mice within the therapeutic dose range. CpG-STAT3dsASO activated intratumoral GAMs, such as dendritic cells, macrophages and microglia, thereby expanding CD4+ Th1 cells while reducing TREG numbers. CpG-STAT3dsASO monotherapy did not have curative effects as it led to recruitment of only limited numbers of mostly exhausted effector CD8+ T cells. However, when combined with systemic PD1 inhibition, CpG-STAT3dsASO/anti-PD1 treatments caused regression of GL261 as well as immunotherapy-resistant QPP8 gliomas and resulted in long-term survival of the majority of mice. The combination treatment boosted CD8+ effector T-cell activity, while promoting their intratumoral interaction with activated CD4+ Th1 cells and activated macrophages as indicated by spatial transcriptomics. Conclusions Our results suggest rationale for GBM immunotherapy using CpG-STAT3dsASO to disrupt GAMs-dependent immune evasion, thereby restoring sensitivity to PD1 blockade and facilitating T-cell-mediated antitumor immune responses.

Year:

2025

Purpose: A glioblastoma (GBM) is a primary brain tumor with significant unmet therapeutic needs. Immune checkpoint inhibitors (ICIs) have marked therapeutic benefits in many different cancers but have yet to show benefit for most GBM patients in phase III trials. Methods: A systematic review querying ClinicalTrials.gov for prospective clinical trials investigating ICI in GBM between 1950 and July 2024 was performed. Search terms comprised 11 distinct ICIs. Data abstracted include clinical trial NCT numbers with study titles and status, enrollment information, interventions, and more. Clinical trial identifying information, interventions, and outcomes were extracted. Results: One hundred and seventeen clinical trials were identified; four were phase 3. Most involved PD-1 or CTLA-4 blockade as monotherapy or in combination with standard-of-care. The large, randomized trials included CHECKMATE 143, CHECKMATE 498, CHECKMATE 548, and NRG BN007. These showed no improvement in median overall survival or progression-free survival in unselected patients. Biomarker-directed analyses suggest that a subset of GBM patients may benefit. Conclusions: ICI for the treatment of GBM has not demonstrated clear evidence of efficacy thus far. This review serves as a quick reference of ICI trial results in GBM. Biomarker-driven patient selection and/or novel approaches to overcome resistance mechanisms remain areas of viable inquiry.

Year:

2024

Supplementary Fig. 6. WHO grade 3 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 is expressed in and out of the perivascular niche, and colocalizes with mural cells in the perivascular niche, in meningiomas with WHO grade 3 histology. SF numbers indicate individual meningiomas. Representative of n=10 WHO grade 3 meningiomas. WHO grade defined using histological criteria. Scale bars, 10µm.

Year:

2024

Supplementary Table S1. Cell cluster marker genes from single-cell RNA sequencing of human meningiomas with loss of chromosome 22q. Supplementary Table S2. Cell cluster marker genes from single-cell RNA sequencing of dog meningiomas. Supplementary Table S3. RNA sequencing differential expression analyses across recurrent versus primary human meningiomas. Supplementary Table S4. Antibodies for multiplexed sequential immunofluorescence. Supplementary Table S5. Cell cluster marker genes from single-cell RNA sequencing of human cells from meningioma xenografts. Supplementary Table S6. Cell cluster marker genes from single-cell RNA sequencing of mouse cells from meningioma xenografts.

Year:

2024

Supplementary Fig. 5. WHO grade 2 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is primarily restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 2 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 2 meningiomas. Scale bars, 10µm.

Year:

2024

Supplementary Fig. 4. WHO grade 1 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 1 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 1 meningiomas. Scale bars, 10µm.

Year:

2024

Supplementary Fig. 13. Analysis of human and mouse cell types from single-cell RNA sequencing of meningioma xenografts. A, Feature plots showing differentially expressed genes across UMAP clusters from CH-157MN meningioma xenograft human cells analyzed using single-cell RNA sequencing. See also Supplementary Table 5. B, Meningioma xenograft human single-cell cluster changes across experimental conditions and biological replicates. Student’s t -tests. C, Single-cell RNA sequencing UMAP of 34,902 meningioma xenograft mouse cell transcriptomes showing microenvironment cell types. D, Feature plots showing differentially expressed genes across UMAP clusters from meningioma xenograft mouse cells analyzed using single-cell RNA sequencing. E, Meningioma xenograft mouse single-cell cluster changes across experimental conditions and biological replicates. See also Supplementary Table 6. Student’s t tests.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (26)

Aparna Bhaduri

Assistant Professor

University of California, Los Angeles

UNITED STATES
View details

Brisa Palikuqi

Assistant Professor

Yale University

UNITED STATES
View details

Alexander H. Stegh

Washington University School of Medicine

UNITED STATES
View details

Craig Horbinski

Northwestern University

UNITED STATES
View details

Hui Zhang

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Jason Miska

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Peter J. Dickinson

-

UNITED STATES
View details

Chad Mirkin

Professor

Northwestern University

UNITED STATES
View details

James Chandler

Vice-Chair

Northwestern University

UNITED STATES
View details

Ophir Klein

Cedars-Sinai Medical Center

UNITED STATES
View details

Rimas V Lukas

Northwestern University

UNITED STATES
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Shawn L. Hervey‐Jumper

Professor

University of California, San Francisco

UNITED STATES
View details

Stephen T. Magill

Assistant Professor

Northwestern University

UNITED STATES
View details

Calixto-Hope G Lucas

Johns Hopkins University School of Medicine

UNITED STATES
View details

Christine M. Toedebusch

University of California

UNITED STATES
View details

Maciej S. Lesniak

Northwestern University

UNITED STATES
View details

Arie Perry

University of California, San Francisco

UNITED STATES
View details

Jared Ahrendsen

Assistant Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Adam M Sonabend

Associate Professor, Director of Translational Neuro-oncology

Northwestern University

UNITED STATES
View details

Marcin Kortylewski

Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Lee A D Cooper

Associate Professor, Director, Computational Pathology

Northwestern University

UNITED STATES
View details

David R Raleigh

University of California, San Francisco

UNITED STATES
View details

Joanna J. Phillips

Profesor

University of California, San Francisco

UNITED STATES
View details

Priya Kumthekar

Northwestern Medicine

UNITED STATES
View details

Derek Wainwright

Associate Professor, Scientific Director for Brain Tumor Research

Loyola University Chicago Stritch School of Medicine

UNITED STATES
View details